Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
DRMA | US
-0.05
-3.11%
Healthcare
Biotechnology
30/06/2024
21/10/2024
1.56
1.51
1.63
1.51
Dermata Therapeutics Inc. a clinical-stage medical dermatology company focuses on identifying developing and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310 which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. Dermata Therapeutics Inc. was incorporated in 2014 and is headquartered in San Diego California.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
105.7%1 month
96.2%3 months
282.4%6 months
2117.1%-
-
0.73
-
-
0.58
-
-
-7.86M
2.36M
2.36M
-
-
-
-
-173.01
0.05
4.63
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.46
Range1M
0.60
Range3M
3.78
Rel. volume
0.67
Price X volume
214.24K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ZVSA | ZVSA | Biotechnology | 2.3 | 2.47M | 0.00% | 0.00 | 0.00% |
Allarity Therapeutics Inc. Common Stock | ALLR | Biotechnology | 1.63 | 2.30M | -5.78% | n/a | 6.68% |
Altamira Therapeutics Ltd. | CYTO | Biotechnology | 0.5751 | 2.17M | -2.53% | 0.32 | 1.54% |
60 Degrees Pharmaceuticals Inc. Common Stock | SXTP | Biotechnology | 1.07 | 1.99M | -1.83% | n/a | 5.19% |
Sorrento Therapeutics Inc | SRNE | Biotechnology | 0.003 | 1.90M | 11.11% | n/a | -101.21% |
Panbela Therapeutics Inc | PBLA | Biotechnology | 0.3354 | 1.76M | 5.14% | 0.00 | -39.69% |
Kiromic BioPharma Inc | KRBP | Biotechnology | 1.1 | 1.70M | -8.33% | n/a | -258.59% |
Innovation Pharmaceuticals Inc | IPIX | Biotechnology | 0.003 | 1.56M | 200.00% | n/a | 20.48% |
CohBar Inc | CWBR | Biotechnology | 0.5 | 1.45M | 0.00% | n/a | 0.00% |
Arch Therapeutics Inc | ARTH | Biotechnology | 0.3002 | 1.33M | 0.00% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.58 | 0.53 | Par |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 0.73 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 282.38 | 72.80 | Riskier |
Debt to Equity | - | -1.23 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 2.36M | 3.66B | Emerging |